Xintela AB (XINT) AI Stock Analysis

• Market Cap: kr223.93M
• Dividend Yield: N/A
• Average Volume (3M): 554.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: -7.68%
• EPS Growth: 17.93%
• Country: SE
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 861,266,850
• 10 Day Avg. Volume: 503,836
• 30 Day Avg. Volume: 554,918
• PEG Ratio: -0.04
• Price to Book (P/B): -6.52
• Price to Sales (P/S): 61.84
• P/FCF Ratio: -4.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.11
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: kr0.28 ▲(0.36% Upside)
• Action: Reiterated Date: 01/14/26
• Date: Action: Reiterated 01/14/26

The score is held down primarily by weak financial performance (shrinking revenue, large ongoing losses, heavy cash burn, and deteriorating negative equity). Technical indicators provide some offset with improving short-term momentum, but valuation remains constrained by negative earnings (negative P/E).

Positive Factors

Low Financial Leverage

Zero reported debt materially lowers refinancing and interest-rate risks over the medium term, preserving flexibility for R&D financing choices. For an early-stage biotech, low leverage improves chances to structure grants, equity or milestone financings without immediate debt-service pressure, aiding durability.

Proprietary Target Platform (α10β1)

A focused, proprietary biological target provides a durable competitive advantage: it creates a clear R&D platform spanning orthopedics and oncology, supports IP build-out, and can enable multiple product/diagnostic opportunities and strategic partnerships that persist beyond short-term cycles.

Gross Profitability on Core Products

Recording positive gross profit indicates the core product economics may be viable once fixed R&D and G&A are scaled or optimized. This suggests potential for sustainable unit-level margins on commercialization, making future profitability achievable if revenue scales and overhead is controlled.

Negative Factors

Persistent Operating Cash Burn

Sustained large negative operating cash flows create structural funding dependence, forcing repeated external raises that dilute shareholders and divert management focus. Without a durable path to positive cash flow or secured long-term funding, R&D timelines and trials risk delay or scale-back over months.

Negative Shareholders' Equity

Negative equity materially weakens balance-sheet resilience and can impair the company’s ability to access favourable financing or enter partnerships. It increases counterparty and investor caution, possibly raising cost of capital and constraining strategic options over the medium term absent recapitalization.

Loss-Making with Revenue Volatility

Persistent operating and net losses combined with volatile and declining revenue signal weak commercialization traction and execution risk. Structural profitability remains distant, making long-term sustainability contingent on either durable revenue growth or significant cost restructuring and successful clinical/commercial milestones.

Xintela AB Business Overview & Revenue Model

Company Description

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.

How the Company Makes Money

Xintela AB primarily generates revenue through the development and commercialization of its proprietary cell therapy products and targeted cancer treatments. The company earns money by partnering with pharmaceutical companies and research institutions to co-develop therapies, licensing its technology, and potentially through future product sales once regulatory approvals are secured. Significant factors contributing to its earnings include collaborative agreements, research grants, and strategic partnerships that support the advancement of its clinical programs. Additionally, Xintela may benefit from milestone payments and royalties from commercialized products developed using its technology.

Xintela AB Financial Statement Overview

Summary

Weak fundamentals: very small and sharply declining TTM revenue (-39.9%), deeply negative EBIT/net income (about -42M), and heavy ongoing cash burn (TTM OCF/FCF around -37M). No debt helps, but equity is meaningfully negative and worsening, indicating limited financial flexibility and reliance on external funding.

Income Statement

TTM (Trailing-Twelve-Months) revenue is small (2.96M) and down sharply versus the prior annual period (revenue growth -39.9% TTM after +53.0% in 2024), indicating a volatile and still-developing commercial base. Profitability remains very weak: TTM EBIT and net income are deeply negative (-41.97M and -42.28M), with a highly negative net margin, showing operating costs far exceed revenue. A positive is that gross profit is strong relative to revenue in the periods with revenue, but it is not translating into bottom-line improvement.

Balance Sheet

The balance sheet shows no total debt in the most recent periods (TTM and 2024), reducing financial leverage risk. However, shareholders’ equity has turned meaningfully negative in TTM (-27.88M) after already being negative in 2024 (-5.95M), which is a major weakness and points to accumulated losses and reduced balance sheet flexibility. Total assets have also declined versus prior years (9.08M TTM vs 24.80M in 2024), suggesting shrinking resources available to fund operations.

Cash Flow

Cash burn remains heavy: TTM operating cash flow and free cash flow are both around -37.0M, indicating ongoing funding needs. Free cash flow improved versus 2024 (positive free cash flow growth of ~26%), but it is still materially negative. Cash flow is roughly in line with reported losses (free cash flow to net income ~1.00), which suggests losses are translating into cash outflows rather than being offset by working-capital or non-cash items.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.28M	4.21M	78.00K	0.00	0.00
Gross Profit	1.68M	4.21M	78.00K	-3.79M	-3.50M
EBITDA	-46.08M	-38.90M	-53.47M	-65.28M	-57.11M
Net Income	-48.56M	-39.19M	-54.08M	-66.22M	-58.93M
Balance Sheet
Total Assets	29.02M	24.80M	18.39M	24.52M	24.74M
Cash, Cash Equivalents and Short-Term Investments	23.21M	16.68M	7.81M	8.34M	9.94M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	34.30M	30.75M	14.02M	18.74M	20.80M
Stockholders Equity	-5.27M	-5.95M	4.38M	5.78M	3.95M
Cash Flow
Free Cash Flow	0.00	-40.70M	-53.22M	-39.60M	-44.15M
Operating Cash Flow	-41.62M	-40.70M	-53.12M	-39.49M	-42.89M
Investing Cash Flow	0.00	0.00	-104.00K	-27.52M	-1.20M
Financing Cash Flow	48.53M	50.09M	51.79M	64.56M	20.43M

Xintela AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Negative. The current price of 0.28 is above the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.29, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.01 is Neutral, neither overbought nor oversold. The STOCH value of 26.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XINT.

Xintela AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XINT	49 Neutral	kr223.93M	-3.93	―	―	-7.68%	17.93%
ISOFOL	49 Neutral	kr202.40M	-2.72	-51.35%	―	―	-34.02%
ELIC	49 Neutral	kr298.01M	-14.87	-48.30%	―	―	52.96%
ACTI	48 Neutral	kr137.34M	-2.09	-1291.15%	―	―	28.54%
IRLAB.A	43 Neutral	kr131.82M	-0.88	-199.86%	―	69.03%	23.10%
MODTX	43 Neutral	kr36.12M	-1.36	-166.94%	―	―	-19.35%